Tagged with R&D

Opinion Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan’s Asia Pacific office, outlines the technological innovations currently driving the drug development pipelines of rare disease companies.   Recent advancements in the development of novel platforms for precise targeting of small molecules, gene therapy, stem cell therapy,…

Korea Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within…

Korea Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive director, Jae Cheon Yeo, explains the crucial role the organization plays in promoting R&D in Korea, the evolution of the…

Korea LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son, explains the reason why he joined the company, his strategy to turn it into a truly global entity, and its…

Korea South Korean heavyweight Daewoong Pharmaceutical saw record sales in 2018, but did see a decrease in its EBITDA figures. To ensure its future profitability, the company has decided to invest heavily in the research of development of new drugs, with a new 100 billion won facility planned.   Daewoong Pharmaceutical’s…

Korea Ten of the top contract research organizations (CROs) currently operating in South Korea, as selected by KoNECT, the Korea National Enterprise for Clinical Trials. Six domestic firms and four international operators make up the top 10.   Made with Visme Infographic Maker     To find out more about Korea’s…

Opinion Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI) in Europe, outlines the value of public-private partnerships in drug research and development and highlights areas where these collaborations are proving their worth in overcoming some of the most challenging threats to our health.    Our collective ability to translate…

Opinion Deloitte’s Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019’s industry trends.   For companies to address mounting pressures, a digital-first mindset will be required to make business operations more efficient and bring transformational therapies to the market.   Digital…

Korea An outline of the geographical distribution of clinical trial sites in South Korea. 184 medical institutions were designated by the Korean government as qualified clinical trial sites in December 2016, 57 of which were in the capital, Seoul.   Within Asia-Pacific, South Korea was the nation with the highest number…

Spain Within the past decade, Spain has developed into a top player in the European clinical trial network. The pharmaceutical industry has been increasing its investment commitment in the market and taking advantage of the country’s outstanding public health system. These activities are being well received by the government, so much…

Opinion Nawal Roy is founder and CEO of Holmusk, a company dedicated to building one of the world’s largest real-world evidence platforms for neurosciences. Here, Nawal Roy discusses the potential for real-world evidence to optimise drug life-cycle management.    Use of real-world evidence (RWE) can modernize the process of drug research, development and delivery.   The…

Malaysia A map showing 18 of the active clinical trials sites in Malaysia in 2017. The sites are spread across the entire nation and cover a variety of therapeutic areas – including gastroenterology / hepatology, cardiology and oncology –  with a cluster of activity in Kuala Lumpur.   In terms of…